Compare KEN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | EVO |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | Singapore | Germany |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 778.3M |
| IPO Year | 2014 | 2007 |
| Metric | KEN | EVO |
|---|---|---|
| Price | $65.88 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 15.1K | ★ 46.0K |
| Earning Date | 05-27-2026 | 04-08-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | $9.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.50 | $1.89 |
| 52 Week High | $95.93 | $4.27 |
| Indicator | KEN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 40.09 |
| Support Level | $64.41 | $1.90 |
| Resistance Level | $70.47 | $2.20 |
| Average True Range (ATR) | 1.28 | 0.05 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 53.02 | 17.74 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include: OPC Power Plants, which generates and supplies electricity and energy in Israel; and CPV Group, which generates and supplies electricity and energy in the United States. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.